Advanced search

Filters

Country

All countries

North America

South America

Europe

Africa

Middle East

Asia

Oceania

Central America

Select all

Capitalization

Sector

All sectors

  Energy

  Basic Materials

  Industrials

  Consumer Cyclicals

  Consumer Non-Cyclicals

  Financials

  Healthcare

  Technology

  Utilities

  Real Estate

  Institutions, Associations & Organizations

  Government Activity

  Academic & Educational Services

Select all

Add a keyword

Announcement Date

Since

Until

925 Results

Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Johnson & Johnson : receives positive CHMP opinion for RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations
PU
Viracta Therapeutics : HST 2024 – Presentation
PU
Transcript : Bank of China Limited, 2023 Earnings Call, Apr 02, 2024
Western New England Bancorp : Proxy Statement
PU
FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
BU
Transcript : Fanhua Inc., Q4 2023 Earnings Call, Mar 20, 2024
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
GL
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
AQ
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
BU
FANHUA to Announce Fourth Quarter and Fiscal Year 2023 Unaudited Financial Results and Host Conference Call on March 20, 2024
AQ
Knight Therapeutics Announces Launch of Bijuva® in Canada
GL
Certain A Shares of ChengDa Pharmaceuticals Co., Ltd. are subject to a Lock-Up Agreement Ending on 20-JAN-2024.
CI
IMFINZI® (durvalumab) plus transarterial chemoembolization (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolization
BU
Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation
BU
TELES Informationstechnologien : Annual Financial Statements 2022
PU
Daiichi Sankyo : Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes(241.9KB
PU
Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes
BU
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
BU
CIFI Holdings Co. Ltd. Announces Director Changes
CI
Certain A Shares of Jiangsu Canopus Wisdom Medical Technology Co.,Ltd. are subject to a Lock-Up Agreement Ending on 30-NOV-2023.
CI
TRUQAP™ (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive breast cancer
BU
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)
BU
IMFINZI® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial
BU
FANHUA Provides Select Preliminary Financial Results and Schedules to Report Third Quarter 2023 Financial Results on November 20, 2023
AQ
Johnson & Johnson : New Data from Phase 3 PAPILLON Study Show RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Resulted in 60% Reduction in Risk of Disease Progression or Death in Patients with Previously Untreated EGFR Exon 20 Insertion Mutation-Positive NSCLC
PU
Ironwood Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting
BU
Datopotamab deruxtecan plus IMFINZI® (durvalumab) demonstrated robust and durable tumor responses in 1st-line treatment of patients with metastatic triple-negative breast cancer in BEGONIA Phase Ib/II trial
BU
Johnson & Johnson : New Data from Phase 3 PAPILLON Study Show RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Resulted in 60% Reduction in Risk of Disease Progression or Death in Patients with Previously Untreated EGFR Exon 20 Insertion Mutation-Positive NSCLC
PU
FantasTech Sale II, Newegg’s Big Fall Extravaganza, Offers Incredible Deals on Must-Have Tech Products
BU
Johnson & Johnson : Landmark Phase 3 MARIPOSA Study Meets Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT® (amivantamab-vmjw) plus Lazertinib Versus Osimertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer
PU
Certain A Shares of Zhe Jiang Headman Machinery Co.,Ltd. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.
CI
Transcript : Fanhua Inc., Q2 2023 Earnings Call, Aug 30, 2023
Fanhua to Announce Second Quarter 2023 Unaudited Financial Results and Host Conference Call on August 30, 2023
AQ
Andes Technology and TetraMem Collaborate to Build Groundbreaking AI Accelerator Chip with Analog In-Memory Computing
AQ
TaChan Securities Co.,Ltd. Announces Changes in the Risk Management Committee Members
CI
Focus Hotmelt Company Ltd. Announces Executive Appointments
CI
AcBel Polytech Inc. acquired GE Power Electronics, Inc. from ABB Ltd for $505 million.
CI
LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in Singapore
AQ
Jinli Group Holdings Limited Announces Directorate Changes
CI
Capivasertib in combination with FASLODEX® (fulvestrant) granted Priority Review in the US for patients with advanced HR-positive breast cancer
BU
Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study
BU
English translation : Board of Directors Report to the Combined General Shareholders Meeting to be held on June 27, 2023 on Stock Options and Restricted Free Shares
PU
Vazyme Signs Global Strategic Cooperation Agreement with Azenta
AQ
Senba Sensing Technology Co.,Ltd. agreed to acquire 67% stake in Wuxi Gelintong Safety Equipment Co., Ltd. from Zhu Wei, Pan Jianxin, Lin Rongxiang, Wu Weining, Fan Jianping, Tang Rong, Yu Biao and Wuxi Ge?an Technology Partnership Enterprise (Limited Partnership) for CNY220 million.
CI
Certain A Shares of Wuxi Autowell Technology Co., Ltd. are subject to a Lock-Up Agreement Ending on 21-MAY-2023.
CI
The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
BU
Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023
BU
ARS Pharmaceuticals : FDA has posted an Addendum to Briefing Document on its website that was circulated to members of the AdCom - Form 8-K
PU
Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week® 2023
BU
Great Lakes Clean Hydrogen Hub Coalition Submits Application for DOE Funding
PR
No results for this search
  1. Stock Market
  2. Advanced search
  3. Lin Ge
  4. News